# Biolinq Safety and Effectiveness Trial

> **NCT06229743** · NA · COMPLETED · sponsor: **Biolinq Inc.** · enrollment: 247 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus

## Interventions

- **DEVICE:** Biolinq System

## Key facts

- **NCT ID:** NCT06229743
- **Lead sponsor:** Biolinq Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-29
- **Primary completion:** 2024-06-10
- **Final completion:** 2024-06-10
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06229743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06229743, "Biolinq Safety and Effectiveness Trial". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06229743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*